GlassScriptPhysician profile
Rajnikant M Patel
NPI 1942220397
$5,135.32
in general payments reported to CMS, 2019-2025
33 companies · $1,384 in 2025
The $1,384 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $790 · 2020: $261 · 2021: $166 · 2022: $431 · 2023: $875 · 2024: $1,228 · 2025: $1,384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,397 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,396.73 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $756.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $594.04 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $496.44 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $483.93 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Sumitomo Pharma America, INC. | $438.66 | 2024-2025 | Gemtesa |
| Amgen INC. | $402.04 | 2019-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $289.38 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.96 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $187.86 | 2022-2025 | |
| Astellas Pharma US INC | $183.85 | 2023-2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $181.02 | 2020-2024 | Eliquis |
| Janssen Pharmaceuticals, INC | $154.50 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $116.49 | 2019-2022 | |
| Pfizer INC. | $84.56 | 2022-2025 | |
| Dexcom, INC. | $82.42 | 2023-2025 | Dexcom G6 Transmitter |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $77.43 | 2024 | Voquezna |
| Xeris Pharmaceuticals, INC. | $59.42 | 2023-2025 | Gvoke Hypopen |
| Gilead Sciences, INC. | $53.27 | 2023-2024 | |
| Abbvie INC. | $42.84 | 2024-2025 | |
| Paratek Pharmaceuticals, INC. | $39.95 | 2025 | Nuzyra |
| Pharmacosmos Therapeutics INC. | $28.01 | 2025 | Monoferric |
| Amarin Pharma, INC. | $23.97 | 2019 | |
| Boston Scientific Corporation | $23.28 | 2025 | Watchman Flx |
| Exact Sciences Corporation | $20.60 | 2025 | Cologuard Collection Kit |
| Advanced Oxygen Therapy INC. | $20.53 | 2023 | Topical Oxygen Chamber For Extremities |
| Inogen, INC. | $19.36 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Takeda Pharmaceuticals U.S.A., INC. | $16.99 | 2025 | Vpriv |
| Otsuka America Pharmaceutical, INC. | $14.70 | 2023 | Rexulti |
| Lundbeck LLC | $13.97 | 2025 | Vyepti |
| Almatica Pharma LLC | $13.50 | 2022 | |
| Daiichi Sankyo INC. | $13.41 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.45 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajnikant Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.